BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 21693436)

  • 21. CSAHi study: Validation of multi-electrode array systems (MEA60/2100) for prediction of drug-induced proarrhythmia using human iPS cell-derived cardiomyocytes -assessment of inter-facility and cells lot-to-lot-variability.
    Nozaki Y; Honda Y; Watanabe H; Saiki S; Koyabu K; Itoh T; Nagasawa C; Nakamori C; Nakayama C; Iwasaki H; Suzuki S; Washio I; Takahashi E; Miyamoto K; Yamanishi A; Endo H; Shinozaki J; Nogawa H; Kunimatsu T
    Regul Toxicol Pharmacol; 2016 Jun; 77():75-86. PubMed ID: 26884090
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High-performance beating pattern function of human induced pluripotent stem cell-derived cardiomyocyte-based biosensors for hERG inhibition recognition.
    Hu N; Wang T; Wang Q; Zhou J; Zou L; Su K; Wu J; Wang P
    Biosens Bioelectron; 2015 May; 67():146-53. PubMed ID: 25153933
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Automated patch clamp on mESC-derived cardiomyocytes for cardiotoxicity prediction.
    Stoelzle S; Haythornthwaite A; Kettenhofen R; Kolossov E; Bohlen H; George M; Brüggemann A; Fertig N
    J Biomol Screen; 2011 Sep; 16(8):910-6. PubMed ID: 21775699
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CSAHi study: Evaluation of multi-electrode array in combination with human iPS cell-derived cardiomyocytes to predict drug-induced QT prolongation and arrhythmia--effects of 7 reference compounds at 10 facilities.
    Kitaguchi T; Moriyama Y; Taniguchi T; Ojima A; Ando H; Uda T; Otabe K; Oguchi M; Shimizu S; Saito H; Morita M; Toratani A; Asayama M; Yamamoto W; Matsumoto E; Saji D; Ohnaka H; Tanaka K; Washio I; Miyamoto N
    J Pharmacol Toxicol Methods; 2016; 78():93-102. PubMed ID: 26657830
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cardiotoxicity Assessment of Drugs Using Human iPS Cell-Derived Cardiomyocytes: Toward Proarrhythmic Risk and Cardio-Oncology.
    Satsuka A; Kanda Y
    Curr Pharm Biotechnol; 2020; 21(9):765-772. PubMed ID: 31264543
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impedance-based detection of beating rhythm and proarrhythmic effects of compounds on stem cell-derived cardiomyocytes.
    Jonsson MK; Wang QD; Becker B
    Assay Drug Dev Technol; 2011 Dec; 9(6):589-99. PubMed ID: 22085047
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Structural and functional screening in human induced-pluripotent stem cell-derived cardiomyocytes accurately identifies cardiotoxicity of multiple drug types.
    Doherty KR; Talbert DR; Trusk PB; Moran DM; Shell SA; Bacus S
    Toxicol Appl Pharmacol; 2015 May; 285(1):51-60. PubMed ID: 25841593
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bridging Functional and Structural Cardiotoxicity Assays Using Human Embryonic Stem Cell-Derived Cardiomyocytes for a More Comprehensive Risk Assessment.
    Clements M; Millar V; Williams AS; Kalinka S
    Toxicol Sci; 2015 Nov; 148(1):241-60. PubMed ID: 26259608
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comprehensive Translational Assessment of Human-Induced Pluripotent Stem Cell Derived Cardiomyocytes for Evaluating Drug-Induced Arrhythmias.
    Blinova K; Stohlman J; Vicente J; Chan D; Johannesen L; Hortigon-Vinagre MP; Zamora V; Smith G; Crumb WJ; Pang L; Lyn-Cook B; Ross J; Brock M; Chvatal S; Millard D; Galeotti L; Stockbridge N; Strauss DG
    Toxicol Sci; 2017 Jan; 155(1):234-247. PubMed ID: 27701120
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Proarrhythmia Risk Assessment in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes Using the Maestro MEA Platform.
    Qu Y; Vargas HM
    Toxicol Sci; 2015 Sep; 147(1):286-95. PubMed ID: 26117837
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiomyocytes from human pluripotent stem cells in regenerative medicine and drug discovery.
    Braam SR; Passier R; Mummery CL
    Trends Pharmacol Sci; 2009 Oct; 30(10):536-45. PubMed ID: 19762090
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An impedance-based cellular assay using human iPSC-derived cardiomyocytes to quantify modulators of cardiac contractility.
    Scott CW; Zhang X; Abi-Gerges N; Lamore SD; Abassi YA; Peters MF
    Toxicol Sci; 2014 Dec; 142(2):331-8. PubMed ID: 25237062
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiotoxicity testing using pluripotent stem cell-derived human cardiomyocytes and state-of-the-art bioanalytics: a review.
    Mandenius CF; Steel D; Noor F; Meyer T; Heinzle E; Asp J; Arain S; Kraushaar U; Bremer S; Class R; Sartipy P
    J Appl Toxicol; 2011 Apr; 31(3):191-205. PubMed ID: 21328588
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impacts of recent advances in cardiovascular regenerative medicine on clinical therapies and drug discovery.
    Murata M; Tohyama S; Fukuda K
    Pharmacol Ther; 2010 May; 126(2):109-18. PubMed ID: 20156482
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Arrhythmogenicity Test Based on a Human-Induced Pluripotent Stem Cell (iPSC)-Derived Cardiomyocyte Layer.
    Slotvitsky M; Tsvelaya V; Frolova S; Dementyeva E; Agladze K
    Toxicol Sci; 2019 Mar; 168(1):70-77. PubMed ID: 30388253
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Application of optical action potentials in human induced pluripotent stem cells-derived cardiomyocytes to predict drug-induced cardiac arrhythmias.
    Lu HR; Hortigon-Vinagre MP; Zamora V; Kopljar I; De Bondt A; Gallacher DJ; Smith G
    J Pharmacol Toxicol Methods; 2017 Sep; 87():53-67. PubMed ID: 28501647
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Human stem cell-derived cardiomyocytes for pharmacological and toxicological modeling.
    Harding SE
    Ann N Y Acad Sci; 2011 Dec; 1245():48-9. PubMed ID: 22211978
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of doxorubicin toxicity on cardiomyocytes using a dual functional extracellular biochip.
    Xiao L; Hu Z; Zhang W; Wu C; Yu H; Wang P
    Biosens Bioelectron; 2010 Dec; 26(4):1493-9. PubMed ID: 20732805
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Determination of appropriate stage of human-induced pluripotent stem cell-derived cardiomyocytes for drug screening and pharmacological evaluation in vitro.
    Shinozawa T; Imahashi K; Sawada H; Furukawa H; Takami K
    J Biomol Screen; 2012 Oct; 17(9):1192-203. PubMed ID: 22706346
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Stem cells for drug screening.
    Laposa RR
    J Cardiovasc Pharmacol; 2011 Sep; 58(3):240-5. PubMed ID: 21499120
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.